NCT06132191|Unknown
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
1 other identifier
R2810-Cemiplimab
Study Type
expanded_access
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredNov 2023
Brief Summary
Provide expanded access of cemiplimab in patients with solid tumors
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 9, 2023
Completed6 days until next milestone
First Posted
Study publicly available on registry
November 15, 2023
CompletedLast Updated
November 20, 2025
Status Verified
November 1, 2025
First QC Date
November 9, 2023
Last Update Submit
November 17, 2025
Conditions
Interventions
CemiplimabDRUG
Also known as: REGN2810
Sponsors & Collaborators
MeSH Terms
Conditions
Carcinoma, Non-Small-Cell LungCarcinoma, Basal Cell
Interventions
cemiplimab
Condition Hierarchy (Ancestors)
Carcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasms, Basal Cell
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 9, 2023
First Posted
November 15, 2023
Last Updated
November 20, 2025
Record last verified: 2025-11